Pages that link to "Template:DocumentData"

The following pages link to Template:DocumentData:

Displaying 50 items.

• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 66 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 68 (transclusion) (← links)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40b Absatz 1 (transclusion) (← links)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40b Absatz 2 (transclusion) (← links)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40b Absatz 3 (transclusion) (← links)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40b Absatz 4 (transclusion) (← links)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40b Absatz 5 (transclusion) (← links)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40b Absatz 6-001 (transclusion) (← links)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 41 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 1 Part 3-002 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 1 Part 4 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 1 Part 5 (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (m) (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (n) (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (o) (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (p) (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (q) (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (r) (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (s) (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 Subpart D (transclusion) (← links)
• Reference:USA 45 CFR Part 46 09-Apr-2025 Subpart B (transclusion) (← links)
• Reference:USA 45 CFR Part 46 09-Apr-2025 Subpart C (transclusion) (← links)
• Reference:USA 45 CFR Part 46 09-Apr-2025 Subpart D (transclusion) (← links)
• Reference:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 V. (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.4.2 (transclusion) (← links)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.3 (transclusion) (← links)
• Reference:WHO WHO - HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) 2005 Page 44 (transclusion) (← links)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 3.42 - recruitment (transclusion) (← links)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 ANNEX I Section K No. 59-60 (transclusion) (← links)
• Reference:EU EMA/786433/2022 Annex V – to guidance for the conduct of good clinical practice inspections – Phase I units 15-Nov-2022 2.9 (transclusion) (← links)
• Reference:EU EMA/298712/2022 - Complex clinical trials – Questions and answers 23-May-2022 Q5.2 (transclusion) (← links)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40 Absatz 2 (transclusion) (← links)
• Reference:DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 33 Absatz 2 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 3 Part 1 1. ; 3. (transclusion) (← links)
• Reference:USA FDA INFORMATION SHEET - Recruiting Study Subjects, Guidance for Institutional Review Boards and Clinical Investigators Jan-1998 - (transclusion) (← links)
• Reference:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 II. Advertising-002 (transclusion) (← links)
• Reference:ICH ICH E8 Guideline R1 (2021) 5.1 (transclusion) (← links)
• Reference:ICH ICH E8 Guideline R1 (2021) 7 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 5 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 6-001 (transclusion) (← links)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 Annex A A.5 (transclusion) (← links)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 Annex A A.6.3-001 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 3 Part 1 1. (i) (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.23 (6) (c) - (d) (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 812.36 (c) (transclusion) (← links)
• Reference:USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 IV A. Adherence (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) GLOSSARY - Blinding/Masking (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) GLOSSARY - Randomisation (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.11 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.15 (transclusion) (← links)